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The coronavirus disease of 2019 (COVID-19) pandemic has so
far  proved  to  be  the  worst  health-related  calamity  seen  by
mankind since the 20th century Spanish Flu. Apparently, origi-
nating in late 2019 from the Chinese province of Wuhan, this
viral  disease  has  since  then  spread  globally  in  a  matter  of
weeks, if not days.1 Currently, majority of the world nations are
overwhelmed with this  catastrophe,  not  only in  terms of  its
impact on the healthcare system, but also the fiscal devastation
that the pandemic has caused, for instance loss of jobs and
small businesses etc. At the time of writing this review, total
number  of  confirmed  cases  infected  with  COVID-19  have
exceeded 12 million, with more than half a million reported
deaths because of the disease itself or its complications. The
situation  in  Pakistan  is  also  alarming,  with  approximately
2,50,000 confirmed cases and nearly 5000 deaths across the
country.
The causative organism in case of COVID-19 infection is severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The
first decade of this millennium witnessed the outbreak of SARS-
CoV, which also started from China, but ultimately spread in 26
countries across five continents.2  SARS-CoV  involved mainly
the respiratory system; therefore, it was naturally assumed by
most authorities that SARS-CoV-2 would also have a similar clin-
ical spectrum, resulting in fever, dyspnea and cough.3 However,
we now know that SARS-CoV-2 behaves like a systemic illness,
and has the potential of involving other vital organs, especially
the liver.4
Non-alcoholic fatty liver disease (NAFLD) is globally being recog-
nised  as  one  of  the  most  common  causes  of  chronic  liver
disease, and is often associated with obesity.5 As the lacunae in
understanding  the  pathogenesis  of  NAFLD  are  increasingly
being  filled,  a  new terminology  named  "MAFLD”  (metabolic
dysfunction-associated fatty liver disease) has been coined by
experts in the field in a recent consensus statement.6 
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As with various other viral illnesses, variable degrees of liver
dysfunction, mostly in the form of elevated transaminase levels
[alanine  aminotransferase  (ALT)  and  aspartate  aminotrans-
ferase (AST)], are commonly found in patients with COVID-19.7
The  contributing  factors  to  this  liver  injury  include  hypoxia
(secondary to COVID pneumonia), the systemic inflammatory
response which is part of the syndrome (usually cell-mediated),
and the use of various drugs as potential anti-viral or supportive
treatments in hospitalised patients, which damage the hepato-
cytes.8 There are other possible mechanisms of liver damage
being extensively studied, including the role of angiotensin-con-
verting  enzyme  2  (ACE2)  receptors  in  bile  ductal  epithelial
injury.9 Whether patients with underlying liver cirrhosis are at a
higher risk of developing further deterioration in liver function is
still a matter of debate.7 However, pre-pandemic studies have
shown that such patients have a higher mortality when they
develop  acute  respiratory  distress  syndrome  (ARDS)  as
opposed to patients with no underlying liver disease.10 In this
context,  given  the  high  prevalence  of  obesity  and  MAFLD,
analysing the severity of COVID-19 infection in the presence of
underlying fatty liver disease becomes even more crucial, as
this can drastically affect the overall disease outcome in such
individuals. 
Over the years, obesity has become a major population health
issue.  Previously  thought  of  as  a  problem of  the  developed
world, many under-developed countries are also facing the chal-
lenge of obesity and its complications, mainly because of the
shift to a more sedentary lifestyle, absence of physical activity,
and consumption of high-calorie processed foods.11 Obese indi-
viduals are at a higher risk of developing respiratory diseases
like  obstructive  sleep  apnea,  obesity  hypoventilation
syndrome, pulmonary embolism (resulting from deep venous
thrombosis)  and  even  community-acquired  pneumonia.12
Therefore, much interest has been evinced in finding out an
association between obesity and severity of COVID-19 infec-
tion.
A study conducted in three hospitals in China during the early
days of the pandemic clearly showed that obese subjects had
more severe form of illness reflected by high C-reactive protein
(CRP)  and  lymphopenia.  These  obese  COVID-19  positive
patients also had a prolonged length of stay in the hospital as
opposed  to  their  non-obese  counterparts.13  Moreover,  the
authors found that there was a 12% increment in the risk of
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developing severe COVID-19 with every one unit escalation in
the body mass index (BMI). Another study, also from China,
clearly elucidated that a higher BMI is associated with more
severe disease manifestations.14
NAFLD (the presence of fat in the liver, after excluding other
causes like significant alcohol consumption or certain drugs) is
a  clinical  spectrum  which  ranges  from  liver  steatosis  to
advanced fibrosis, cirrhosis and even hepatocellular carcinoma
(HCC).15  However,  patients  with  NAFLD  often  have  other
metabolic derangements like presence of type 2 Diabetes mell-
itus, hypertension, dyslipidemia and obesity.14 It was also found
that this subset of patients progressed rapidly to liver cirrhosis
and its complications. Therefore, the term MAFLD was intro-
duced as a practical terminology to identify such patients and to
minimise their risk factors more aggressively in order to prevent
liver decompensation.16
There are a fair amount of upcoming data regarding the poten-
tial association of MAFLD with COVID-19 disease severity. One
retrospective analysis presented data of 202 confirmed cases
of COVID-19 (diagnosed by SARS-COV-2 PCR in throat swab).17
This study showed that although liver injury in majority of the
COVID  positive  patients  was  of  a  relatively  milder  nature,
patients with concomitant MAFLD had a higher probability of
liver  dysfunction  and  increased  risk  of  disease  progression.
Moreover, the same study revealed that these patients shed
their virus for a prolonged period of time as compared to individ-
uals without underlying MAFLD. Another study on 310 subjects
(approximately one-third of which were MAFLD patients) looked
at the association between the degree of fibrosis (based fibro-
sis-4 {FIB-4)} index and NAFLD fibrosis score) and severity of
COVID infection. Here also, the results showed that the severity
of illness markedly increased (in terms of high CRP, lympho-
penia and thrombocytopenia) in MAFLD patients with moderate
or high fibrosis scores.18 The authors hypothesised that MAFLD
with significant liver fibrosis could potentially aggravate the
cytokine storm triggered by the viable virus,  which may be
responsible for illness severity.
The impact of age on the severity of COVID-19 patients with
MAFLD was analysed by a multicentre study, which broadly
divided  patients  into  two  groups:  younger  (<60  years)  and
elderly (>60 years). Interestingly, the authors concluded that
younger individuals had a positive correlation between MAFLD
and the severity of COVID-19; whereas, no such association was
found among older patients with NAFLD.19 Again, the postulated
mechanism explaining this phenomenon may be the hepatic
immune  responses  (involving  the  activation  of  dendritic
cells,  T-lymphocytes,  natural  killer  cells  and  macrophages),
resulting in raised cytokine levels seen in patients with MAFLD.20
These immune responses are more robust in younger subjects;
hence, the likelihood of such patients going into cytokine storm
is higher as against  to older people.  However,  due to small
sample size of this study, the validity of results may not be truly
established.
There are a lot of grey areas in research as far as MAFLD and
COVID-19 are concerned. Firstly, validity of most studies may
not be truly established as most published studies have got a
modest  sample  size  and;  hence,  lesser  generalisability  of
results. Secondly, it is so far not very evident whether MAFLD,
with or without obesity, is alone responsible for the catastrophic
outcome in patients with COVID-19. These individuals may also
have coexisting chronic illnesses like type 2 Diabetes mellitus,
hypertension and hyperlipidemias, which can further aggra-
vate the viral illness.21 Finally, there is a deficiency of informa-
tion regarding previous history of  liver  disease in COVID-19
patients as a whole.22  This becomes even more intricate for
patients with MAFLD as most of them remain undetected in the
initial phase, when the disease is asymptomatic.  
COVID-19 has posed an immense burden on the entire world,
both in terms of the disease and its complications, as well as the
exorbitant financial implications associated with it. Internation-
ally, many healthcare systems are on the verge of collapse due
to  the  universal  pandemic.  Considering  the  fact  that  global
prevalence of obesity and MAFLD is also on the rise, a significant
proportion of the world population could be in danger of devel-
oping grave complications of COVID-19. At this point of time, we
may merely be witnessing the tip of the iceberg. Therefore, it is
highly imperative that further high quality research with larger
sample size be conducted in  order  to  fully  comprehend the
disease pathophysiology; and eventually work towards effec-
tive disease control and prevention.
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